FDA approves first drug to treat patients with rare lung condition

The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. It is the first FDA-approved treatment for this rare lung condition.

From http://besthealthnews.com/2019/09/fda-approves-first-drug-to-treat-patients-with-rare-lung-condition/?utm_source=rss&utm_medium=rss&utm_campaign=fda-approves-first-drug-to-treat-patients-with-rare-lung-condition

from
https://healthnews010.wordpress.com/2019/09/07/fda-approves-first-drug-to-treat-patients-with-rare-lung-condition/

From https://jamesjohnson10.blogspot.com/2019/09/fda-approves-first-drug-to-treat.html

from
https://jamesjohnson10.wordpress.com/2019/09/07/fda-approves-first-drug-to-treat-patients-with-rare-lung-condition/